tetano
Editor, Senior Moderator
J Infect Chemother
. 2026 Feb 16:102932.
doi: 10.1016/j.jiac.2026.102932. Online ahead of print.
Comparison of baloxavir/marboxil treatment and treatment with other anti-influenza agents in adult patients hospitalized for influenza: An internet-based, prospective, multicenter, cohort study in Japan
Masafumi Seki[SUP] 1 [/SUP], Akihiro Ito[SUP] 2 [/SUP], Maiko Osawa[SUP] 3 [/SUP], Yukiko Oya[SUP] 4 [/SUP], Yuki Shiko[SUP] 3 [/SUP], Kazuhiro Tateda[SUP] 5 [/SUP], Jiro Fujita[SUP] 6 [/SUP], Kosaku Komiya[SUP] 7 [/SUP], Akihiko Kawana[SUP] 8 [/SUP], Koichi Izumikawa[SUP] 9 [/SUP], Toshiaki Kikuchi[SUP] 10 [/SUP], Norio Ohmagari[SUP] 11 [/SUP], Mitsuhiro Yamada[SUP] 12 [/SUP], Takaya Maruyama[SUP] 13 [/SUP], Takahiro Takazono[SUP] 9 [/SUP], Makoto Miki[SUP] 14 [/SUP], Yoshitsugu Miyazaki[SUP] 15 [/SUP], Yoshitaka Yamazaki[SUP] 16 [/SUP], Hiroshi Kakeya[SUP] 17 [/SUP], Yuta Hayashi[SUP] 18 [/SUP], Hideaki Nagai[SUP] 19 [/SUP], Tadashi Ishida[SUP] 2 [/SUP]
Affiliations
Introduction: Influenza remains a huge clinical issue, but new anti-influenza agents, such as baloxavir/marboxil (BXM), have recently become available in Japan. The objective of this study was to clarify the clinical differences of hospitalized patients treated by BXM and other anti-influenza agents (non-BXM), such as neuraminidase inhibitors (NAIs).
Methods: The clinical data of patients who were severely ill with influenza and required hospitalization were gathered and analyzed between September 2019 and August 2024 (6 influenza seasons) using an internet surveillance system. From them, patients who were treated by BXM were extracted.
Results: Of the total 490 severe influenza patients, 57 (11.6%) were treated by BXM. The BXM-treated patients had more secondary bacterial pneumonia, but their general conditions were better, compared with the non-BXM-treated patients (433 patients, 88.4%). Age, male/female ratio, vaccination rate, intrafamilial transmission, virus type, and antibiotic use were similar between the two groups, but two or more anti-influenza agents were used more often in the BXM group than in the non-BXM group. Two fatal cases occurred in the BXM group; both were elderly, non-vaccinated, had underlying diseases, and received delayed anti-influenza agents without antibiotics.
Conclusions: BXM was used for patients with secondary bacterial pneumonia, although their general conditions were better, and antibiotic use was similar, although more anti-influenza agents were used than in non-BXM-treated patients. BXM might be one of the treatment options for severe influenza patients requiring hospitalization in the real world.
Keywords: Baloxavir/marboxil; General condition; Influenza; Neuraminidase inhibitor; Secondary bacterial pneumonia.
. 2026 Feb 16:102932.
doi: 10.1016/j.jiac.2026.102932. Online ahead of print.
Comparison of baloxavir/marboxil treatment and treatment with other anti-influenza agents in adult patients hospitalized for influenza: An internet-based, prospective, multicenter, cohort study in Japan
Masafumi Seki[SUP] 1 [/SUP], Akihiro Ito[SUP] 2 [/SUP], Maiko Osawa[SUP] 3 [/SUP], Yukiko Oya[SUP] 4 [/SUP], Yuki Shiko[SUP] 3 [/SUP], Kazuhiro Tateda[SUP] 5 [/SUP], Jiro Fujita[SUP] 6 [/SUP], Kosaku Komiya[SUP] 7 [/SUP], Akihiko Kawana[SUP] 8 [/SUP], Koichi Izumikawa[SUP] 9 [/SUP], Toshiaki Kikuchi[SUP] 10 [/SUP], Norio Ohmagari[SUP] 11 [/SUP], Mitsuhiro Yamada[SUP] 12 [/SUP], Takaya Maruyama[SUP] 13 [/SUP], Takahiro Takazono[SUP] 9 [/SUP], Makoto Miki[SUP] 14 [/SUP], Yoshitsugu Miyazaki[SUP] 15 [/SUP], Yoshitaka Yamazaki[SUP] 16 [/SUP], Hiroshi Kakeya[SUP] 17 [/SUP], Yuta Hayashi[SUP] 18 [/SUP], Hideaki Nagai[SUP] 19 [/SUP], Tadashi Ishida[SUP] 2 [/SUP]
Affiliations
- PMID: 41707847
- DOI: 10.1016/j.jiac.2026.102932
Introduction: Influenza remains a huge clinical issue, but new anti-influenza agents, such as baloxavir/marboxil (BXM), have recently become available in Japan. The objective of this study was to clarify the clinical differences of hospitalized patients treated by BXM and other anti-influenza agents (non-BXM), such as neuraminidase inhibitors (NAIs).
Methods: The clinical data of patients who were severely ill with influenza and required hospitalization were gathered and analyzed between September 2019 and August 2024 (6 influenza seasons) using an internet surveillance system. From them, patients who were treated by BXM were extracted.
Results: Of the total 490 severe influenza patients, 57 (11.6%) were treated by BXM. The BXM-treated patients had more secondary bacterial pneumonia, but their general conditions were better, compared with the non-BXM-treated patients (433 patients, 88.4%). Age, male/female ratio, vaccination rate, intrafamilial transmission, virus type, and antibiotic use were similar between the two groups, but two or more anti-influenza agents were used more often in the BXM group than in the non-BXM group. Two fatal cases occurred in the BXM group; both were elderly, non-vaccinated, had underlying diseases, and received delayed anti-influenza agents without antibiotics.
Conclusions: BXM was used for patients with secondary bacterial pneumonia, although their general conditions were better, and antibiotic use was similar, although more anti-influenza agents were used than in non-BXM-treated patients. BXM might be one of the treatment options for severe influenza patients requiring hospitalization in the real world.
Keywords: Baloxavir/marboxil; General condition; Influenza; Neuraminidase inhibitor; Secondary bacterial pneumonia.